BPI and its congeners as radiation mitigators and radiation protectors

Patent metadata

Field	Value
Publication number	US-9770484-B2
Application number	US-201615169969-A
Country	US
Kind code	B2
Filing date	Jun 1, 2016
Priority date	Apr 5, 2011
Publication date	Sep 26, 2017
Grant date	Sep 26, 2017

Abstract

Described herein is a method of mitigating, in a subject (individual), tissue injury resulting from exposure to radiation (accidental/unintentional or intentional, such as therapeutic), chemoradiotherapy, disease, toxin, or drug or biologic mediated therapy.

First claim

We claim:

1. A method for bone marrow recovery in a subject, the method comprising: administering to a subject in need thereof bactericidal/permeability increasing protein (BPI) and/or its congeners in an amount effective for bone marrow recovery in the subject.

2. The method of claim 1 , wherein the subject has a deficiency in one or more hematopoietic cell types or lineages.

3. The method of claim 1 , wherein the subject has a hematopoietic deficiency comprising lymphopenia, myelopenia, leukopenia, neutropenia, erythropenia, megakaryopenia, a deficiency in platelets, a deficiency in monocytes, a deficiency in lymphocytes, a deficiency in erythrocytes, deficiency in neutrophils, a deficiency in T cells, a deficiency in granulocytes, and/or a deficiency in dendritic cells.

4. The method of claim 3 , wherein the deficiency in one or more hematopoietic cell types or lineages results from exposure to radiation, chemoradiotherapy, radiotherapy, disease, toxin or drug or biologic-mediated therapy.

5. The method of claim 1 , wherein BPI congeners is selected from the group consisting of rBPI 21 , rBPI 23 , rBPI 50 , rBPI(10-193)ala 132 and a N-terminal fragment of BPI having a molecular weight approximately between 20 to 25 kD.

6. The method of claim 1 , further comprising administering an antibiotic.

7. The method of claim 6 , wherein the antibiotic is a quinolone antibiotic.

8. The method of claim 7 , wherein the quinolone antibiotic is selected from the group consisting of moxifloxacin, ciprofloxacin, levofloxacin, garenoxacin, and delafloxacin.

9. The method of claim 1 , wherein BPI and/or its congeners is administered orally, intravenously, or subcutaneously.

10. A method for stimulating hematopoiesis in a subject, the method comprising: administering to a subject in need thereof bactericidal/permeability increasing protein (BPI) and/or its congeners in an amount effective to stimulate hematopoiesis in the subject.

11. The method of claim 10 , wherein the subject has a deficiency in one or more hematopoietic cell types or lineages.

12. The method of claim 10 , wherein the subject has a hematopoietic deficiency comprising lymphopenia, myelopenia, leukopenia, neutropenia, erythropenia, megakaryopenia, a deficiency in platelets, a deficiency in monocytes, a deficiency in lymphocyctes, a deficiency in erythrocytes, deficiency in neutrophils, a deficiency in T cells, a deficiency in granulocytes, and/or a deficiency in dendritic cells.

13. The method of claim 12 , wherein the deficiency in one or more hematopoietic cell types or lineages results from exposure to radiation, chemoradiotherapy, radiotherapy, disease, toxin or drug or biologic-mediated therapy.

14. The method of claim 10 , wherein BPI congeners is selected from the group consisting of rBPI 21 , rBPI 23 , rBPI 50 , rBPI(10-193)ala 132 and a N-terminal fragment of BPI having a molecular weight approximately between 20 to 25 kD.

15. The method of claim 10 , further comprising administering an antibiotic.

16. The method of claim 15 , wherein the antibiotic is a quinolone antibiotic.

17. The method of claim 16 , wherein the quinolone antibiotic is selected from the group consisting of moxifloxacin, ciprofloxacin, levofloxacin, garenoxacin, and delafloxacin.

18. The method of claim 10 , wherein BPI and/or its congeners is administered orally, intravenously, or subcutaneously.

Assignees

• Dana Farber Cancer Inst Inc
• Children'S Medical Center Corp

Inventors

• Guinan Eva
• Levy Ofer

Classifications

• A61P39/00

  General protective or antinoxious agents · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P7/06

  Antianaemics · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title